meRfi®-GM
Cancer immunotherapy / Immuno-Oncology & Breast Cancer / Mammacarcinoma (TNBC)
Welcome to meRfi-GM!
meRfi-GM provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
Navigation
Contents
Several immune strategies have been investigated in TNBC, including co-inhibitory molecules beyond PD1-PD-L1 axis, co-stimulatory checkpoints, cancer vaccines, adoptive cell transfer, combination therapies, as well as different routes of administration. Most of approaches showed signs of anti-cancer activity and a good safety profile in early-phase clinical trials. Since Cancer Immunotherapy / Immuno-Oncology provided benefit only to a small subgroup of Breast Cancer / Mammacarcinoma (TNBC) patients so far, identifying predictive biomarkers is a priority to refine patient-selection. Data from ongoing clinical trials, with the grad…
References (Sources)
- Emerging drugs for the treatment of triple-negative breast cancer: a focus on phase II immunotherapy trials
- Immunotherapy and breast cancer: an overview
- Integrating immunotherapy in the (neo)adjuvant setting of early breast cancer
- Investigational immunomodulatory drugs for enhancement of triple negative breast cancer (TNBC) immunotherapy: early phase development
- Novel immune targets for the treatment of triple-negative breast cancer
- Potential role of immunotherapy for advanced breast cancer
- Research progress on immunotherapy in triple‑negative breast cancer (Review)